Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy

Bortezomib (BTZ), a proteasome inhibitor, is widely used in the treatment of multiple myeloma (MM), but a fraction of patients respond poorly to this agent. To identify factors predicting the duration of progression-free survival (PFS) of MM patients on BTZ treatment, the expression of proteasome an...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, T, Ri, M, Masaki, A, Mori, F, Ito, A, Kusumoto, S, Ishida, T, Komatsu, H, Iida, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735074/
https://www.ncbi.nlm.nih.gov/pubmed/26636288
http://dx.doi.org/10.1038/bcj.2015.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735074/
https://www.ncbi.nlm.nih.gov/pubmed/26636288
http://dx.doi.org/10.1038/bcj.2015.98

Ejemplares similares